Form 4: NextCure Executive Granted Stock Options

Sol Langermann, Chief Scientific Officer of NextCure, Inc., was granted employee stock options on March 29, 2024.

Summary

• Sol Langermann, the Chief Scientific Officer of NextCure, Inc., was granted 93,900 employee stock options on March 29, 2024.
• The exercise price of the options is $2.23.
• The options vest in full on March 29, 2025, one year after the grant date.
• The options expire on March 28, 2034.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes key personnel. The sentiment is slightly positive as it suggests confidence in the company's future.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for a Chief Scientific Officer at a company like NextCure.
• Comparable companies such as Arcus Biosciences and Gritstone Bio also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Scientific Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates